Katherine Z Isoardi1,2,3, Gregory Polkinghorne1,2, Keith Harris1,2, Geoffrey K Isbister3,4. 1. Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 2. Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia. 3. Clinical Toxicology Research Group, University of Newcastle, Newcastle, New South Wales, Australia. 4. Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.
Abstract
AIMS: With rising use worldwide, pregabalin is increasingly implicated in poisoning deaths. We aimed to investigate the clinical effects and complications of pregabalin poisoning. METHODS: This is a retrospective review of patients presenting with pregabalin poisoning to two tertiary toxicology units from 1 July 2014 to 30 June 2019. Patients were identified from prospective databases maintained by both units and data were extracted from these in addition to medical records. RESULTS: There were 488 presentations in 413 patients (237 [57%] male) over the five-year period. The median age was 41 years (IQR 31-50 years). Deliberate self-poisonings accounted for 342 (70%) presentations, with 121 (25%) recreational exposures. Recreational exposures increased over the period from 2 (4%) in the first year to 54 (39%) presentations in the final year. The median dose of pregabalin was 1200 mg (IQR 600-3000 mg, range 75-16 800 mg). Co-ingestions occurred in 427 (88%) presentations, with sedating agents being co-ingested in 387 (79%)-most commonly opioids and benzodiazepines in 201 (41%) and 174 (36%) presentations respectively. Coma (GCS < 9) occurred in 89 (18%) cases, with 52 (11%) patients being intubated. Only one (0.2%) of these patients had not co-ingested a sedating agent. Hypotension occurred in 26 (5%) cases, all with co-ingestants. Seizures occurred in 11 (2%) cases, 3/59 (5%) in pregabalin-only overdoses. The median length of stay was 16.5 hours (IQR 10-25 hours). CONCLUSIONS: Pregabalin overdose does not cause severe toxicity, but rather mild sedation and, uncommonly, seizures. Coma is common in the presence of sedating co-ingestants. Recreational use is increasing.
AIMS: With rising use worldwide, pregabalin is increasingly implicated in poisoning deaths. We aimed to investigate the clinical effects and complications of pregabalinpoisoning. METHODS: This is a retrospective review of patients presenting with pregabalinpoisoning to two tertiary toxicology units from 1 July 2014 to 30 June 2019. Patients were identified from prospective databases maintained by both units and data were extracted from these in addition to medical records. RESULTS: There were 488 presentations in 413 patients (237 [57%] male) over the five-year period. The median age was 41 years (IQR 31-50 years). Deliberate self-poisonings accounted for 342 (70%) presentations, with 121 (25%) recreational exposures. Recreational exposures increased over the period from 2 (4%) in the first year to 54 (39%) presentations in the final year. The median dose of pregabalin was 1200 mg (IQR 600-3000 mg, range 75-16 800 mg). Co-ingestions occurred in 427 (88%) presentations, with sedating agents being co-ingested in 387 (79%)-most commonly opioids and benzodiazepines in 201 (41%) and 174 (36%) presentations respectively. Coma (GCS < 9) occurred in 89 (18%) cases, with 52 (11%) patients being intubated. Only one (0.2%) of these patients had not co-ingested a sedating agent. Hypotension occurred in 26 (5%) cases, all with co-ingestants. Seizures occurred in 11 (2%) cases, 3/59 (5%) in pregabalin-only overdoses. The median length of stay was 16.5 hours (IQR 10-25 hours). CONCLUSIONS:Pregabalinoverdose does not cause severe toxicity, but rather mild sedation and, uncommonly, seizures. Coma is common in the presence of sedating co-ingestants. Recreational use is increasing.
Authors: Rose Crossin; Debbie Scott; Shalini Arunogiri; Karen Smith; Paul M Dietze; Dan I Lubman Journal: Med J Aust Date: 2018-11-22 Impact factor: 7.738
Authors: Michael A Downes; Colin B Page; Ingrid Berling; Ian M Whyte; Geoffrey K Isbister Journal: Clin Toxicol (Phila) Date: 2019-10-11 Impact factor: 4.467
Authors: Geoffrey K Isbister; Lena E Friberg; Barrie Stokes; Nicholas A Buckley; Christopher Lee; Naren Gunja; Simon G Brown; Ellen MacDonald; Andis Graudins; Anna Holdgate; Stephen B Duffull Journal: Ann Emerg Med Date: 2007-08-23 Impact factor: 5.721
Authors: Caroline Daly; Eve Griffin; Darren M Ashcroft; Roger T Webb; Ivan J Perry; Ella Arensman Journal: Clin Drug Investig Date: 2018-04 Impact factor: 2.859